Peptide Impurity Profiles: What the Small Peaks Actually Tell You (2026)
The impurity peaks on a chromatogram are not just noise subtracted from a purity number — they are a record of how the peptide was made and how it has aged. Deletion sequences, truncations, oxidation products, and counter-ion adducts each leave a recognizable signature. This is a research-framed reading of what those signatures reveal about synthesis and storage.
A purity percentage collapses everything that is not the target peptide into a single complementary number — 98% pure means 2% something else, and the COA usually stops there. But that 2% is not anonymous. It is a specific set of byproducts, each one a fingerprint of a particular step in how the peptide was synthesized or how it has aged since. Learning to read the impurity profile turns the leftover percentage from a vague deduction into an informative record. This is research-use educational content; nothing here is a dosing recommendation or human-use claim.
If you want the underlying methods first, our HPLC explainer and HPLC vs mass spectrometry guide cover how impurities are detected and identified in the first place.
Purity is one number; the profile is the story
Two samples can both report 98% purity and be in genuinely different shape. In one, the 2% might be benign residual solvent left from purification. In the other, the same 2% might be a closely related deletion sequence — a near-copy of the target missing one amino acid. The headline number treats those as equivalent. The impurity profile does not.
This is the central idea: the purity percentage tells you how much impurity; the profile tells you what kind. And the kind matters, because different impurities point to different causes, carry different implications, and are spotted by different analytical signatures.
Stop reading "98% pure" as "2% mystery." Read it as "2% of something specific." The identity of that something — synthesis byproduct, degradation product, or process residual — is what an impurity profile makes visible, and it often says more about a vendor's process than the headline figure.
The main families of peptide impurities
Most impurities in a research peptide fall into a handful of recognizable categories. Each is detected through a combination of where it appears on the chromatogram and what mass it carries.
Deletion and truncation sequences
Solid-phase peptide synthesis builds a chain one amino acid at a time, coupling each new residue to the growing chain. When a coupling step is incomplete, a fraction of the chains skip that residue — producing a deletion sequence missing one amino acid. A chain that stopped growing entirely partway through is a truncation.
These are the most informative synthesis-related impurities precisely because they are so close to the target. A single-residue deletion differs from the intended peptide by exactly that residue's mass, so on mass spectrometry it shows up as a peak shifted down by a known amount. On HPLC it often elutes near the main peak, since removing one residue usually changes the molecule's behavior only slightly. A profile heavy in deletion sequences points back to coupling efficiency during synthesis — a process signal, not a storage one.
Oxidation products
Certain amino acids — methionine, cysteine, and tryptophan especially — are chemically susceptible to oxidation. An oxidation product is the target peptide with one or more oxygen atoms added at such a site. Its mass is shifted upward by the mass of the added oxygen, a clean signature on mass spectrometry.
Oxidation is read differently from a deletion sequence. Where deletions implicate synthesis, a growing oxidation peak often implicates handling and storage — exposure to air, light, or warmth after the peptide was made. So an oxidation-dominated profile can be an aging signal, which connects to everything in our stability testing and storage coverage. The same vendor's fresh batch and an old vial can have meaningfully different oxidation content.
Aggregation and related-substance peaks
Peptides can associate with each other into dimers and higher aggregates, and some carry structural variants such as disulfide-bond scrambling in cysteine-containing sequences. These show up as peaks distinct from the monomer — sometimes at very different retention times or masses. Aggregation is partly a stability phenomenon and partly sequence-dependent, and a profile with a notable aggregate peak is worth understanding rather than dismissing.
Process-related residuals: TFA and counter-ions
Not every impurity is a damaged peptide. TFA (trifluoroacetic acid) is widely used in peptide synthesis and purification, and it can remain associated with the peptide as a counter-ion or adduct. It is generally a process-related residual — a consequence of the purification chemistry — rather than a structural defect in the peptide itself. Residual solvents fall in the same category. These tell you about the manufacturing and purification route, and they are part of why a complete characterization considers a sample's salt form and residual-reagent status, not just its area-percent purity.
How the profile is actually read
Identifying these families is exactly the case for pairing two techniques rather than relying on one. HPLC tells you how many impurity peaks there are, how large each is, and where it sits relative to the main peak. Mass spectrometry tells you what each impurity is by its mass — a deletion (mass down by one residue), an oxidation (mass up by oxygen), an adduct (mass up by the counter-ion). Neither answers the full question alone, which is the whole argument of our HPLC vs mass spectrometry piece.
The integration choices behind those peak sizes matter too. An impurity hidden under a tailing or poorly resolved main peak can vanish from the profile entirely, making a sample look cleaner than it is — the mechanism is detailed in our peak integration guide. So a credible impurity profile depends on a method that actually resolves the impurities it is meant to characterize.
A profile dominated by near-main-peak impurities of consistent size points toward synthesis (deletion/truncation). A profile where the impurity that grew is an oxidation product points toward handling and storage. Residual solvent or counter-ion signals point toward the purification route. The location and identity of the impurity, not just its size, is what carries the meaning.
Why this matters for sourcing decisions
The practical payoff is that the impurity profile distinguishes between two failure modes that the purity number conflates. A vendor whose impurities are mostly process residuals has a clean synthesis with a purification choice you can understand. A vendor whose impurities are mostly deletion sequences has a coupling-efficiency problem in the synthesis itself. And a sample whose impurities are mostly oxidation products may simply be old, or stored poorly — which is as much a shipping and handling question as a quality one, tied to the cold-chain and storage discussions.
For research that depends on consistent inputs, asking for the profile — not just the percentage — is the higher-resolution check. For compound-specific context and the vendors worth verifying at this level, see the catalog entries for BPC-157 and tirzepatide, the buy-peptides overview, and the research methodology page.
Bottom line
The impurity profile is the detail behind the purity headline. Deletion and truncation sequences read as synthesis signals; oxidation products read as aging or handling signals; TFA and residual solvents read as purification-route signals. Two samples with identical purity numbers can carry completely different profiles — and the profile, read with HPLC for size and mass spectrometry for identity, often tells you more about how a peptide was made and how it has aged than the single number ever could.
A buyer who reads only the percentage sees a deduction. A buyer who reads the profile sees the manufacturing and storage history written into the leftover few percent.
For laboratory research use only. Not for human consumption.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Related guides:
- HPLC vs Mass Spectrometry — how impurities are sized and identified
- HPLC Peak Integration & Purity Math — how impurity peaks affect the number
- How Peptide Stability Is Tested — where oxidation and aging impurities come from
- Peptide Storage & Shelf Life — keeping degradation impurities low
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
How Peptides Are Synthesized and Tested: From SPPS to HPLC and Mass Spec (2026)
A research-framed walkthrough of how research peptides are made (solid-phase peptide synthesis) and how their purity and identity are verified (HPLC and mass spectrometry) — the chemistry behind every Certificate of Analysis.
Third-Party Peptide Lab Testing Explained: How Independent Verification Actually Works (2026)
Sending a vial to an outside lab is the closest thing the research peptide market has to an audit. Here is how third-party testing works end to end — what gets measured, identity vs purity vs sterility, chain of custody, and how to read the result you get back.
LC-MS for Peptide Identity Confirmation: How Two Instruments Work as One (2026)
LC-MS is not a single test but two analytical methods wired together — liquid chromatography to separate, mass spectrometry to identify. Here is how the hyphenated technique works, what each half contributes, and how to read an LC-MS result that confirms a peptide is the molecule you think it is.